rhythm

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and…

2 weeks ago

Jinsha Site Museum Draws 120,000 Visitors During the National Day Holiday with Its Widely Praised ‘Qing Rhythm: An Invitation from Jinsha’ Event

CHENGDU, China, Oct. 15, 2025 /PRNewswire/ -- A news report from CRI Online: On the afternoon of October 8th, at…

5 months ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase…

8 months ago

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

July 09, 2025 16:16 ET  | Source: Rhythm Pharmaceuticals, Inc. BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc.…

8 months ago